Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $30

4/22/24 7:21:21 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $26 to $30.

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TARA

Date	Price Target	Rating	Analyst
4/16/2025	$12.00	Sector Outperform	Scotiabank
3/14/2025		Overweight	Cantor Fitzgerald
7/10/2023	$22.00	Buy	Guggenheim
11/8/2021	$32.00 → $34.00	Outperform	Oppenheimer